相关实验视频
Updated: Sep 9, 2025

04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
571
通过空气污染物促进莱维体痴呆症
Xiaodi Zhang1,2,3, Haiqing Liu1,2, Xiao Wu4
1Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
概括
空气污染,特别是细颗粒物 (PM2.5),显著增加了勒维体痴呆症 (LBD) 的风险. 这种环境暴露会在大脑中触发有害的α-synuclein蛋白菌株,
科学领域:
- 环境健康
- 神经科学
- 毒理学
背景情况:
- 空气污染与一般痴呆风险有关.
- 空气污染对莱维体痴呆症 (LBD) 的具体影响尚不清楚.
- 阿尔法-同核素 (αSyn) 蛋白聚合是LBD的一个标志.
研究的目的:
- 调查细颗粒物 (PM2.5) 暴露与勒维体痴呆症 (LBD) 风险之间的联系.
- 探索PM2.5和LBD病变之间的机制联系.
- 确定PM2.5暴露是否可以诱导致病性αSyn菌株.
主要方法:
- 在美国对大量人群 (565万个人) 进行分析,以评估PM2.5暴露和LBD风险.
- 使用暴露于PM2.5的野生类型和αSyn缺乏小鼠的体内研究.
- 通过PM2.5暴露产生的αSyn菌株的生物化学表征,包括蛋白酶K耐药性和神经毒性测定.
- 对PM2.5暴露的小鼠和LBD患者进行转录组分析.
主要成果:
- 在大量人群中,PM2.5暴露与LBD风险的增加有显著关联.
- 在野生类型的小鼠中,PM2.5暴露导致大脑缩,但在αSyn缺乏的小鼠中却没有.
- 暴露于PM2.5产生了一种致病性αSyn菌株 (PM- PFF),其特性与LBD相似.
- 全球诱导的病原性αSyn菌株和神经毒性.
- 在暴露于PM2.5的小鼠和LBD患者之间观察到共享的转录组特征.
结论:
- 细颗粒物 (PM2.5) 是莱维体痴呆症 (LBD) 的重要环境危险因素.
- 暴露于PM2.5可以启动有毒αSyn菌株的形成,导致LBD病变.
- 减少空气污染对于减轻LBD等神经疾病的负担至关重要.
相关概念视频
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.0K
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K

